<PAGE> 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 13F
Form 13F COVER PAGE
Report for Calendar Year or Quarter Ended: September 30, 1998
Check here if Amendment [ X ]; Amendment Number: 1
This Amendment (Check only one.): [ X ] is a restatement.
[ ] adds new holdings
entries.
Institutional Investment Manager Filing this Report:
Name: BB Biotech AG
Address: Vordergasse 3
Grafenauweg 4
Zug, Switzerland CH-6301
Form 13F File Number: 28-6964
The institutional investment manager filing this report and the person by whom
it is signed hereby represent that the person signing the report is authorized
to submit it, that all information contained herein is true, correct and
complete, and that it is understood that all required items, statements,
schedules, lists, and tables are considered integral parts of this form.
Person Signing this Report on Behalf of Reporting Manager:
Name: Daniel Bugmann
Title: SIGNING AUTHORITY
Phone: (41-41) 724-5959
Signature, Place, and Date of Signing:
/s/ DANIEL BUGMANN Zug, Switzerland 18 May 1999
- -------------------- ----
<PAGE> 2
Report Type (Check only one.):
[ ] 13F HOLDINGS REPORT. (Check here if all holdings of this reporting
manager are reported in this report.)
[ ] 13F NOTICE. (Check here if no holdings reported are in this report,
and all holdings are reported by other reporting manager(s).)
[XX] 13F COMBINATION REPORT. (Check here if a portion of the holdings for
this reporting manager are reported in this report and a portion are
reported by other reporting manager(s).)
List of Other Managers Reporting for this Manager:
Name
Biotech Focus S.A.
Biotech Invest S.A.
-2-
<PAGE> 3
Form 13F SUMMARY PAGE
Report Summary:
Number of Other Included Managers: 2
Form 13F Information Table Entry Total: 13
Form 13F Information Table Value Total:$580,698
(thousands)
List of Other Included Managers:
Provide a numbered list of the name(s) and Form 13F file number(s) of all
institutional investment managers with respect to which this report is filed,
other than the manager filing this report.
No. Name
1 Biotech Focus S.A.
2 Biotech Invest S.A.
<PAGE> 4
BB BIOTECH AG
30-SEP-98 FORM 13F INFORMATION TABLE
<TABLE>
<CAPTION>
- ----------------------------------------------------------------------------------------------
COLUMN 5:
------------------------------
COLUMN 4:
COLUMN 1: COLUMN 2: COLUMN 3: VALUE
NAME OF ISSUER TITLE OF CLASS CUSIP (X$1,000) SHRS OR SH/ PUT/
PRN AMT PRN CALL
- ----------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C> <C>
Alexion
Pharmaceuticals
Inc. Common Stock 01535110 $ 16,873 1,824,113 SH
- ----------------------------------------------------------------------------------------------
Ariad
Pharmaceuticals
Inc. Common Stock 04033A10 $ 6,251 2,273,000 SH
- ----------------------------------------------------------------------------------------------
Aurora
Biosciences,
Inc. Common Stock 05192010 $ 8,529 1,421,500 SH
- ----------------------------------------------------------------------------------------------
Aviron Common Stock 05376210 $ 40,992 2,655,286 SH
- ----------------------------------------------------------------------------------------------
Biochem
Pharma,
Inc. Common Stock 09058T10 $ 126,558 6,887,500 SH
- ----------------------------------------------------------------------------------------------
Clinichem
Development,
Inc. Common Stock 18690610 $ 807 172,178 SH
- ----------------------------------------------------------------------------------------------
CV
Therapeutics,
Inc. Common Stock 12666710 $ 11,325 1,969,647 SH
- ----------------------------------------------------------------------------------------------
La Jolla
Pharmaceutical
Company Common Stock 50345910 $ 8,685 3,021,000 SH
- ----------------------------------------------------------------------------------------------
<CAPTION>
- -------------------------------------------------------------------------------------------
COLUMN 8:
COLUMN 6: COLUMN 7: VOTING AUTHORITY
INVESTMENT OTHER MANAGERS ----------------------------------------
COLUMN 1: DISCTRETION
NAME OF ISSUER SOLE SHARED NONE
- -------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C>
Alexion
Pharmaceuticals
Inc. DEFINED 1,824,113 NONE NONE
- -------------------------------------------------------------------------------------------
Ariad
Pharmaceuticals
Inc. DEFINED 2,273,000 NONE NONE
- -------------------------------------------------------------------------------------------
Aurora
Biosciences,
Inc. DEFINED 1,421,500 NONE NONE
- -------------------------------------------------------------------------------------------
Aviron DEFINED 2 2,655,286 NONE NONE
- -------------------------------------------------------------------------------------------
Biochem
Pharma,
Inc. DEFINED 1 6,887,500 NONE NONE
- -------------------------------------------------------------------------------------------
Clinichem
Development,
Inc. DEFINED 172,178 NONE NONE
- -------------------------------------------------------------------------------------------
CV
Therapeutics,
Inc. DEFINED 1,969,647 NONE NONE
- -------------------------------------------------------------------------------------------
La Jolla
Pharmaceutical
Company DEFINED 3,021,000 NONE NONE
- -------------------------------------------------------------------------------------------
</TABLE>
<PAGE> 5
<TABLE>
<S> <C> <C> <C> <C> <C> <C>
- -----------------------------------------------------------------------------------------------
MedImmune,
Inc. Common Stock 58469910 $ 252,072 3,893,000 SH
- -----------------------------------------------------------------------------------------------
Sugen, Inc. Common Stock 86504110 $ 6,942 534,000 SH
- -----------------------------------------------------------------------------------------------
Synsorb
Biotech, Inc. Common Stock 87160V10 $ 5,438 2,115,810 SH
- -----------------------------------------------------------------------------------------------
Transkaryotic
Therapies, Inc. Common Stock 89373510 $ 67,476 2,811,500 SH
- -----------------------------------------------------------------------------------------------
Vertex
Pharmaceuticals,
Inc. Common Stock 92532F10 $ 28,750 1,250,000 SH
- -----------------------------------------------------------------------------------------------
COLUMN
TOTALS $580,698
- -----------------------------------------------------------------------------------------------
</TABLE>
<TABLE>
<S> <C> <C> <C> <C> <C>
- -----------------------------------------------------------------------------------------
MedImmune,
Inc. DEFINED 1 3,893,000 NONE NONE
- -----------------------------------------------------------------------------------------
Sugen, Inc. DEFINED 534,000 NONE NONE
- -----------------------------------------------------------------------------------------
Synsorb
Biotech, Inc. DEFINED 2,115,810 NONE NONE
- -----------------------------------------------------------------------------------------
Transkaryotic
Therapies, Inc. DEFINED 2 2,811,500 NONE NONE
- -----------------------------------------------------------------------------------------
Vertex
Pharmaceuticals,
Inc. DEFINED 2 1,250,000 NONE NONE
- -----------------------------------------------------------------------------------------
COLUMN
TOTALS
- -----------------------------------------------------------------------------------------
</TABLE>
